Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial

被引：0

作者：

Harry Raftopoulos

William Cooper

Erin O’Boyle

Nashat Gabrail

Ralph Boccia

Richard J. Gralla

机构：

[1] Hofstra North Shore-LIJ School of Medicine,Albert Einstein College of Medicine

[2] TFS International,undefined

[3] FibroGen,undefined

[4] Inc.,undefined

[5] Gabrail Cancer Center,undefined

[6] Center for Cancer and Blood Disorders,undefined

[7] Jacobi Medical Center,undefined

来源：

Supportive Care in Cancer | 2015年 / 23卷

关键词：

Cancer; Chemotherapy-induced nausea and vomiting (CINV); Extended-release; Granisetron; Subcutaneous; APF530;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：723 / 732

页数：9

共 50 条

[41] Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial
Tsuji, Daiki
Suzuki, Kenichi
Kawasaki, Yohei
Goto, Koichi
Matsui, Reiko
Seki, Nobuhiko
Hashimoto, Hironobu
Hama, Toshihiro
Yamanaka, Takeharu
Yamamoto, Nobuyuki
Itoh, Kunihiko
SUPPORTIVE CARE IN CANCER, 2019, 27 (03) : 1139 - 1147
[42] Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)
Hisanori Shimizu
Kenichi Suzuki
Takeshi Uchikura
Daiki Tsuji
Takeharu Yamanaka
Hironobu Hashimoto
Koichi Goto
Reiko Matsui
Nobuhiko Seki
Toshikazu Shimada
Shunya Ikeda
Naoki Ikegami
Toshihiro Hama
Nobuyuki Yamamoto
Tadanori Sasaki
Journal of Pharmaceutical Health Care and Sciences, 4 (1)
[43] NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
Matti Aapro
Meinolf Karthaus
Lee Schwartzberg
Igor Bondarenko
Tomasz Sarosiek
Cristina Oprean
Servando Cardona-Huerta
Vincent Hansen
Giorgia Rossi
Giada Rizzi
Maria Elisa Borroni
Hope Rugo
Supportive Care in Cancer, 2017, 25 : 1127 - 1135
[44] NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
Aapro, Matti
Karthaus, Meinolf
Schwartzberg, Lee
Bondarenko, Igor
Sarosiek, Tomasz
Oprean, Cristina
Cardona-Huerta, Servando
Hansen, Vincent
Rossi, Giorgia
Rizzi, Giada
Borroni, Maria Elisa
Rugo, Hope
SUPPORTIVE CARE IN CANCER, 2017, 25 (04) : 1127 - 1135
[45] Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study
Seol, Young Mi
Kim, Hyo Jeong
Choi, Young Jin
Lee, Eun Mi
Kim, Yang Soo
Oh, Sung Yong
Koh, Su Jin
Baek, Jin Ho
Lee, Won Sik
Joo, Young Don
Lee, Hyun Gi
Yun, Eun Young
Chung, Joo Seop
SUPPORTIVE CARE IN CANCER, 2016, 24 (02) : 945 - 952
[46] The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial
Zhaocai Yu
Wenchao Liu
Ling Wang
Houjie Liang
Ying Huang
Xiaoming Si
Helong Zhang
Duhu Liu
Hongmei Zhang
Supportive Care in Cancer, 2009, 17 : 99 - 102
[47] Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study
Young Mi Seol
Hyo Jeong Kim
Young Jin Choi
Eun Mi Lee
Yang Soo Kim
Sung Yong Oh
Su Jin Koh
Jin Ho Baek
Won Sik Lee
Young Don Joo
Hyun Gi Lee
Eun Young Yun
Joo Seop Chung
Supportive Care in Cancer, 2016, 24 : 945 - 952
[48] A randomized, double-blind, placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Jeon, So Yeon
Han, Hye Sook
Bae, Woo Kyun
Park, Moo-Rim
Lee, Sang-Cheol
Go, Se-Ii
Yun, Hwan Jung
Ryu, Hyewon
Im, Yong-Jin
Song, Eun-Kee
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[49] The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial
Yu, Zhaocai
Liu, Wenchao
Wang, Ling
Liang, Houjie
Huang, Ying
Si, Xiaoming
Zhang, Helong
Liu, Duhu
Zhang, Hongmei
SUPPORTIVE CARE IN CANCER, 2009, 17 (01) : 99 - 102
[50] Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial.
Hashimoto, Hironobu
Yamanaka, Takeharu
Shimada, Yasuhiro
Arata, Koji
Matsui, Reiko
Goto, Koichi
Takiguchi, Tomomi
Ohyanagi, Fumiyoshi
Kogure, Yuki
Nogami, Naoyuki
Nakao, Masahiko
Takeda, Koji
Azuma, Kanako
Nagase, Seisuke
Hayashi, Toshinobu
Fujiwara, Kimiko
Shimada, Toshikazu
Seki, Nobuhiko
Suzuki, Kenichi
Yamamoto, Nobuyuki
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →